4D Molecular Therapeutics Competitors, Revenue, Alternatives and Pricing

Claim your profile


Total Funding:$111.6M
Lead Investor(s):CureDuchenne Ventures

City Ranking

Industry Ranking

Growjo 10k Ranking

Estimated Revenue & Financials

  • 4D Molecular Therapeutics's estimated annual revenue is currently $13.8M per year.
  • 4D Molecular Therapeutics received $0.5M in venture funding in September 2018.
  • 4D Molecular Therapeutics's estimated revenue per employee is $155,000
  • 4D Molecular Therapeutics's total funding is $111.6M.

Employee Data

  • 4D Molecular Therapeutics has 89 Employees.
  • 4D Molecular Therapeutics grew their employee count by 0% last year.
  • 4D Molecular Therapeutics currently has 8 job openings.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingOnline ReviewPricing
Geron Corporati...
Rigel Pharmaceu...
Althea Technolo...
INOVA Diagnosti...
10X Genomics
ProTrials Resea...
Advanced Cell D...
The J. Craig Ve...
CellMax Life
Missing a competitor? Contribute!?

The mission of 4D Molecular Therapeutics is to design and develop transformative gene therapy products using our proprietary technology to create novel adeno-associated virus variants to be utilized as treatments for serious unmet medical conditions. Our products are unlocking the full potential of gene therapy to treat, and potentially cure, genetic diseases. A large number of patients and diseases, who previously were not treatable by gene therapy, will be addressable by 4D products. 4D has one of the deepest and most diverse product pipelines in the gene therapy field. Adeno-associated virus (AAV) vectors have emerged as a favored delivery vehicle for gene therapy in the human body. They can deliver the genes for therapeutic proteins to accessible tissues in the body and are generally considered safe. Several AAV gene therapy products are in late-stage clinical development, and one product is approved in the EU (Glybera, Uniqure). However, these first-generation AAV vectors have limited utility for the majority of diseases. Many of these common AAV were discovered as laboratory contaminants and monkey infections, for example; they have not been customized as targeted medicines. In contrast, 4D customized AAV vectors, and the products made from them, are designed to unlock the full potential of gene therapy. Through 4D's Therapeutic Vector Evolution, we are able to create customized vectors solutions to overcome the hurdles identified with first-generation AAV vectors. 4D is creating the ultimate gene therapy products to cure genetic diseases using new customized delivery vehicles (vectors) to shuttle genes into the cells in any organ in the body. This 4D library of vectors will soon include several for the liver, several for the brain, several for the heart, the eye, muscle, and so on. Doctors will be able to hand pick a vector for any patient based on the organ that is diseased.

keywords:Biotechnology,Cleantech,Healthcare,Pharmaceuticals,Wind Power


Number of Employees


Revenue (est)


Current Jobs


Employee Growth %


Total Funding







4D Molecular Therapeutics News

09/05/2019 - Genetic Modification Therapies Market Business Growth and ...

Genetic Modification Therapies Market Business Growth and Top Key Players like: 4D Molecular Therapeutics, Abeona Therapeutics, Allergan, ...

09/03/2019 - Going Viral: The Next Generation of AAV Vectors

Developed by Spark Therapeutics, Luxturna is an AAV2-based gene ... These procedures formed the basis of 4D Molecular Therapeutics, ...

08/29/2019 - Genetic Modification Therapies Clinical Applications Market ...

Genetic Modification Therapies Clinical Applications Market Poised to Exhibit High CAGR by 2026 – 4d Molecular Therapeutics LLC, Abeona ...

4D Molecular Therapeutics Funding

DateAmountRoundLead InvestorsReference
2017-09-20$3.0MUndisclosedCystic Fibrosis Foundation Therapeutics IncArticle
2018-09-06$90.0MBViking Global InvestorsArticle
2018-09-10$0.5MUndisclosedCureDuchenne VenturesArticle

4D Molecular Therapeutics Executive Hires

2019-02-20Fred KamalCTO, CFOArticle